Litcius/Paper detail

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial

Emmanuela E. Ambrose, Teresa Latham, Primrose Songoro, Mwesige Charles, Adam Lane, Susan E. Stuber, Abel Makubi, Russell E. Ware, Luke R. Smart

2023The Lancet Haematology33 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTranscranial DopplerTanzaniaStroke (engine)Clinical endpointPediatricsPopulationSickle cell anemiaPlaceboClinical trialInternal medicineDiseasePathologyEnvironmental healthEnvironmental planningEngineeringEnvironmental scienceMechanical engineeringAlternative medicineHemoglobinopathies and Related DisordersMyeloproliferative Neoplasms: Diagnosis and TreatmentIron Metabolism and Disorders
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial | Litcius